|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
CA2744096C
(en)
|
1996-07-31 |
2013-07-30 |
Laboratory Corporation Of America Holdings |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
|
CZ296845B6
(cs)
|
1997-05-28 |
2006-07-12 |
Aventis Pharmaceuticals Inc. |
Derivát chinolinu a chinoxalinu, farmaceutický prostredek obsahující tento derivát a pouzití
|
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドｇｌｐ−１アゴニスト
|
|
CA2393896A1
(en)
|
1999-09-15 |
2001-03-22 |
Warner-Lambert Company |
Pteridinones as kinase inhibitors
|
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
AU2002359714B2
(en)
|
2001-12-18 |
2006-12-21 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
|
|
ES2333702T3
(es)
|
2001-12-24 |
2010-02-26 |
Astrazeneca Ab |
Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
|
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
|
US7265378B2
(en)
|
2002-07-10 |
2007-09-04 |
E. I. Du Pont De Nemours And Company |
Electronic devices made with electron transport and/or anti-quenching layers
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
KR20050056227A
(ko)
|
2002-10-03 |
2005-06-14 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
MXPA05007503A
(es)
|
2003-01-17 |
2005-09-21 |
Warner Lambert Co |
Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
|
|
EP1620413A2
(en)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
MXPA05012281A
(es)
|
2003-05-14 |
2006-05-19 |
Torreypines Therapeutics Inc |
Compuestos y uso de los mismos en la modulacion beta amiloide.
|
|
RU2330851C9
(ru)
|
2003-05-23 |
2008-10-20 |
Центарис Гмбх |
ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
|
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
|
EP1646383A4
(en)
|
2003-07-21 |
2009-03-25 |
Bethesda Pharmaceuticals Inc |
DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
|
|
EP1673092B1
(en)
|
2003-10-17 |
2007-08-15 |
4 Aza Ip Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
JP4890255B2
(ja)
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
|
MXPA06005687A
(es)
|
2003-11-20 |
2006-08-17 |
Janssen Pharmaceutica Nv |
2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
|
|
JP2007512275A
(ja)
|
2003-11-24 |
2007-05-17 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピラゾリルおよびイミダゾリルピリミジン
|
|
MXPA06007326A
(es)
|
2003-12-23 |
2007-01-26 |
Astex Therapeutics Ltd |
Derivados de pirazol como moduladores de proteina cinasa.
|
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
|
BRPI0514691A
(pt)
|
2004-08-31 |
2008-06-17 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
|
|
MX2007004276A
(es)
*
|
2004-10-14 |
2007-05-16 |
Hoffmann La Roche |
1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.
|
|
EP1830869B1
(en)
|
2004-12-24 |
2013-05-22 |
Spinifex Pharmaceuticals Pty Ltd |
Method of treatment or prophylaxis
|
|
CA2597447C
(en)
|
2005-02-14 |
2014-03-25 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
EP1853261B1
(de)
|
2005-03-03 |
2017-01-11 |
Universität des Saarlandes |
Selektive hemmstoffe humaner corticoidsynthasen
|
|
CA2606017A1
(en)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1881981A1
(en)
*
|
2005-05-18 |
2008-01-30 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
EP1957487A1
(de)
|
2005-11-11 |
2008-08-20 |
AEterna Zentaris GmbH |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
EP1966214B9
(en)
|
2005-12-21 |
2017-09-13 |
Janssen Pharmaceutica N.V. |
Triazolopyridazines as tyrosine kinase modulators
|
|
JP2009535393A
(ja)
*
|
2006-05-01 |
2009-10-01 |
ファイザー・プロダクツ・インク |
置換２−アミノ縮合複素環式化合物
|
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
|
CA2653117A1
(en)
|
2006-05-24 |
2007-11-29 |
Boehringer Ingelheim International Gmbh |
Substituted pteridines substituted with a four-membered heterocycle
|
|
JP2009541460A
(ja)
|
2006-07-03 |
2009-11-26 |
ベレナギング ヴォー クリスタラク ホガー オンダーヴェイル ヴェーテンザパーリク オンダージーク エン パシェンテンゾーク |
ヒスタミンｈ４受容体と相互作用する縮合二環式化合物
|
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
１，５−ナフチリジン化合物及び有機発光素子
|
|
WO2008076278A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Methods of cancer treatment with igf1r inhibitors
|
|
JP2010514695A
(ja)
|
2006-12-21 |
2010-05-06 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物および方法およびそのための適応症
|
|
CA2673003A1
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Quinazolines for pdk1 inhibition
|
|
AU2007337886C1
(en)
|
2006-12-22 |
2014-10-16 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as FGFR inhibitors
|
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
|
EP2150255A4
(en)
|
2007-05-10 |
2011-10-05 |
Glaxosmithkline Llc |
CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
|
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
|
JP2010529031A
(ja)
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
|
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
|
WO2008155378A1
(en)
|
2007-06-21 |
2008-12-24 |
Janssen Pharmaceutica Nv |
Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
|
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
|
EP2173354A4
(en)
|
2007-08-09 |
2011-10-05 |
Glaxosmithkline Llc |
CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2009064835A1
(en)
|
2007-11-16 |
2009-05-22 |
Incyte Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
|
CA2722992A1
(en)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
|
EP2282995B1
(en)
|
2008-05-23 |
2015-08-26 |
Novartis AG |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
|
JP2012509342A
(ja)
|
2008-11-20 |
2012-04-19 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
|
|
CA2750047A1
(en)
|
2009-01-21 |
2010-07-29 |
Basilea Pharmaceutica Ag |
Novel bicyclic antibiotics
|
|
EP2391623A4
(en)
*
|
2009-02-02 |
2012-09-05 |
Merck Sharp & Dohme |
HAMMER OF ACT ACTIVITY
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
HRP20230248T1
(hr)
|
2009-06-12 |
2023-04-14 |
Abivax |
Spojevi korisni za liječenje preranog starenja, te naročito progerije
|
|
CA2772714C
(en)
|
2009-09-03 |
2017-09-26 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
WO2011026579A1
(en)
|
2009-09-04 |
2011-03-10 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
EP2332939A1
(en)
*
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
|
RU2017144535A
(ru)
|
2010-03-30 |
2019-02-18 |
Версеон Корпорейшн |
Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
US8513421B2
(en)
|
2010-05-19 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
|
WO2011149937A1
(en)
|
2010-05-24 |
2011-12-01 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN102532141A
(zh)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
|
|
EP2670753B1
(en)
|
2011-01-31 |
2016-10-19 |
Novartis AG |
Novel heterocyclic derivatives
|
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ， インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US9249110B2
(en)
|
2011-09-21 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
PH12014500912A1
(en)
|
2011-10-28 |
2014-06-09 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
*
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
HUE053653T2
(hu)
|
2014-03-26 |
2021-07-28 |
Astex Therapeutics Ltd |
FGFR inhibitor és IGF1R inhibitor kombinációi
|
|
MX370099B
(es)
|
2014-03-26 |
2019-12-02 |
Astex Therapeutics Ltd |
Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|